Intravenous Immunoglobulin-Associated Hemolytic Anemia
| Autor: | Jessica Kneib, Amy P. Gabbard, Jeremy Jacobs |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Hemolytic anemia Anemia Hemolytic medicine.medical_specialty Anemia Clinical Biochemistry Gastroenterology Packed Red Blood Cell Transfusion 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine Humans Medicine Basic metabolic panel Adverse effect Purpura Thrombocytopenic Idiopathic medicine.diagnostic_test business.industry Biochemistry (medical) Immunoglobulins Intravenous Complete blood count Middle Aged medicine.disease Thrombocytopenic purpura Hemolysis 030104 developmental biology Female business 030215 immunology |
| Zdroj: | Laboratory Medicine. 51:e47-e50 |
| ISSN: | 1943-7730 0007-5027 |
| DOI: | 10.1093/labmed/lmaa019 |
| Popis: | Intravenous immunoglobulin (IVIG) is an important therapeutic tool for the treatment of a variety of conditions, including immune thrombocytopenic purpura (ITP). Although IVIG has many approved indications and is typically well tolerated, a number of adverse effects have been reported. Hemolysis is a documented but under-recognized adverse effect associated with large individual or cumulative doses of IVIG. Hemolytic complications are typically mild and detected incidentally when screening tests, such as a complete blood count (CBC) showing decreased hemoglobin or a complete metabolic panel (CMP) resulting in elevated bilirubin, are performed for another reason. Herein, we report a case of significant hemolytic anemia in a 59 year old Caucasian woman, who required packed red blood cell transfusion after administration of IVIG for the treatment of ITP. Increased awareness of the potential for clinically significant hemolysis after the use of moderate cumulative doses of IVIG is needed, particularly in patients with risk factors for hemolysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|